☰

Empresas y finanzas

Ackman seeks court ruling on Allergan special meeting


    (Reuters) - William Ackman's Pershing Square Capital Management said it had filed a lawsuit seeking confirmation that a requested special shareholder meeting of Allergan Inc's shareholders would not trigger Allergan's poison pill takeover defense.

    The Botox maker has rejected a $53 billion joint offer from Ackman and Canadian drugmaker Valeant Pharmaceuticals International.

    ALLERGAN (AGN.NY)said in April that its board had adopted a one-year shareholder rights plan to give it more time to consider takeover proposals.

    Allergan's shareholder rights plan will trigger if a person or group acquires 10 percent or more of its shares.

    The lawsuit filed in Delaware Court of Chancery followed a request to Allergan from Pershing Square on June 6 seeking confirmation that Allergan would not use its poison pill to impede Ackman's request for a special meeting.

    A response from Allergan?s counsel on Thursday did not provide that confirmation, Pershing Square said.

    Allergan rejected a sweetened offer from Valeant and the activist investor on Tuesday.

    (Reporting by Natalie Grover and Sweta Singh; Editing by Ted Kerr)